These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 3458006)

  • 1. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
    Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006
    [No Abstract]   [Full Text] [Related]  

  • 2. Parathyroid hormone in aluminum bone disease: a comparison of parathyroid hormone assays.
    Andress DL; Endres DB; Ott SM; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S87-90. PubMed ID: 3458004
    [No Abstract]   [Full Text] [Related]  

  • 3. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 5. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients].
    Nakazawa R
    Clin Calcium; 2004 May; 14(5):738-43. PubMed ID: 15577035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of aluminum on bone and cell localization.
    Cournot-Witmer G; Plachot JJ; Bourdeau A; Lieberherr M; Jorgetti V; Mendes V; Halpern S; Hemmerle J; Drüeke T; Balsan S
    Kidney Int Suppl; 1986 Feb; 18():S37-40. PubMed ID: 3457993
    [No Abstract]   [Full Text] [Related]  

  • 8. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH; Faugere MC; Smith AJ; Friedler RM
    Kidney Int Suppl; 1986 Feb; 18():S70-3. PubMed ID: 3458000
    [No Abstract]   [Full Text] [Related]  

  • 9. Aluminium-induced osteomalacia in severe chronic renal failure (SCRF).
    Visser WJ; Van de Vyver FL
    Clin Nephrol; 1985; 24 Suppl 1():S30-6. PubMed ID: 3915958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of plasma aluminum in the detection and prevention of aluminum toxicity.
    Winney RJ; Cowie JF; Robson JS
    Kidney Int Suppl; 1986 Feb; 18():S91-5. PubMed ID: 3458005
    [No Abstract]   [Full Text] [Related]  

  • 11. The interaction of parathyroid hormone and aluminum in renal osteodystrophy.
    Slatopolsky E
    Kidney Int; 1987 Mar; 31(3):842-54. PubMed ID: 3573543
    [No Abstract]   [Full Text] [Related]  

  • 12. Aluminum in chronic hemodialysis. Possible influence on osteomalacic bone disease.
    Quarello F; Giachino G; Bossi P; Gilli G; Corrao G; Scursatone E; Jeantet A; Bossi R; Coppo R; Piccoli G; Vercellone A
    Minerva Nefrol; 1980; 27(4):635-44. PubMed ID: 7254691
    [No Abstract]   [Full Text] [Related]  

  • 13. Aluminum and renal bone disease in Australia.
    Dunstan CR; Evans RA
    Kidney Int Suppl; 1986 Feb; 18():S65-9. PubMed ID: 3457999
    [No Abstract]   [Full Text] [Related]  

  • 14. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Toxic effect of aluminum in chronic renal failure].
    Głuszek J
    Pol Tyg Lek; 1987 Nov; 42(48):1499-502. PubMed ID: 3451199
    [No Abstract]   [Full Text] [Related]  

  • 16. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dialysis osteomalacia and aluminum toxicity: a form of renal osteodystrophy.
    Felsenfeld AJ
    ANNA J; 1985 Jun; 12(3):189-91. PubMed ID: 3848318
    [No Abstract]   [Full Text] [Related]  

  • 18. Aluminum-induced dialysis osteodystrophy: the demise of "Newcastle bone disease"?
    Kerr DN; Ward MK; Arze RS; Ramos JM; Grekas D; Parkinson IS; Ellis HA; Owen JP; Simpson W; Dewar J
    Kidney Int Suppl; 1986 Feb; 18():S58-64. PubMed ID: 3457998
    [No Abstract]   [Full Text] [Related]  

  • 19. [Adynamic bone disease in kidney failure. Role of aluminum].
    Cohen-Solal ME; Sebert JL; Morinière P; Fournier A
    Rev Rhum Ed Fr; 1993 May; 60(5):361-4. PubMed ID: 8167643
    [No Abstract]   [Full Text] [Related]  

  • 20. Osteomalacia and bone disease arising from aluminum.
    Coburn JW; Norris KC; Nebeker HG
    Semin Nephrol; 1986 Mar; 6(1):68-89. PubMed ID: 3110896
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.